NYU Langone Health, Department of Medicine, New York, NY, USA; Pfizer Inc, New York, NY, USA.
NYU Langone Health, Department of Medicine, New York, NY, USA.
Clin Ther. 2021 Feb;43(2):360-368.e5. doi: 10.1016/j.clinthera.2020.12.008. Epub 2020 Dec 18.
The COVID-19 pandemic has been widely reported to present stress to medical systems globally and to disrupt the lives of patients and health care practitioners (HCPs). Given that spontaneous reporting heavily relies on both HCPs and patients, an understandable question is whether the stress of the pandemic has diminished spontaneous reporting. Herein, the hypothesis that the COVID-19 pandemic has negatively affected the spontaneous reporting of adverse drug events was assessed.
Spontaneous-report counts from 119 weeks (January 1, 2018, to April 12, 2020) were identified using Pfizer's safety database and were analyzed. Autoregressive integrated moving-average models were fitted to aggregated and disaggregated time series (TSs). Model residuals were charted on individual-value and moving-range charts and exponentially weighted moving-average charts for the identification of statistically unexpected changes associated with the pandemic.
Overall, the reporting of serious adverse events showed no unexpected decline. Total global reporting declined, driven by HCP reporting (of both serious and nonserious events), starting after week 8 of 2020 and exceeding model expectations by week 15 of 2020, suggesting the pandemic as an assignable cause. However, reporting remained within longer-term historical ranges. The TS from Japan was the only national TS that showed a significant decline, and an unusual periodicity related to national holidays. A few countries, notably Taiwan, showed unexpected statistical increases in reporting associated with the pandemic, commencing as early as week 3 of 2020. In the literature, the reporting of adverse drug events was stable. Ancillary findings included prevalent year-end/beginning reporting minima, with more reports from HCPs than from consumers.
Using data from a large-scale and diverse safety database from a pharmaceutical company, a significant global decline in total reporting was detected, driven by HCPs, not consumers, and reports of nonserious events, consistent with the pandemic as an assignable cause, but the reporting remained within long-term ranges, suggesting relative durability. Importantly, the analyses found no unexpected decline in overall reporting of serious events. Future avenues of research include the use of data from large-scale, publicly available spontaneous reporting systems for assessing the generalizability of the present findings and whether they correlate with impaired signal detection, as well as a follow-up analysis of whether the effects on spontaneous reporting abate after the pandemic.
COVID-19 大流行已被广泛报道对全球医疗系统造成压力,并扰乱了患者和医疗保健从业者(HCP)的生活。鉴于自发报告在很大程度上依赖于 HCP 和患者,一个可以理解的问题是,大流行的压力是否减少了自发报告。在此,评估了 COVID-19 大流行是否对不良药物事件的自发报告产生负面影响的假设。
使用辉瑞的安全数据库,从 119 周(2018 年 1 月 1 日至 2020 年 4 月 12 日)中确定自发报告计数,并进行分析。自回归综合移动平均模型被拟合到聚合和离散时间序列(TS)。模型残差在个体值和移动范围图以及指数加权移动平均图上进行绘制,以识别与大流行相关的统计上意外的变化。
总体而言,严重不良事件的报告没有出现意外下降。全球报告总数下降,主要是由于 2020 年第 8 周后 HCP 报告(包括严重和非严重事件)下降,到 2020 年第 15 周超过模型预期,表明大流行是一个可归因的原因。然而,报告仍在长期历史范围内。来自日本的 TS 是唯一显示出显著下降的国家 TS,并且与国家假期有关的异常周期性。一些国家,特别是中国台湾,显示出与大流行相关的意外统计增加,早在 2020 年第 3 周就开始出现。在文献中,药物不良反应报告保持稳定。辅助发现包括普遍的年终/年初报告最小值,来自 HCP 的报告多于来自消费者的报告。
使用来自一家制药公司的大规模和多样化安全数据库中的数据,检测到总报告的显著全球下降,主要由 HCP 而非消费者驱动,以及非严重事件的报告,与大流行作为一个可归因的原因一致,但报告仍在长期范围内,表明相对耐久性。重要的是,分析发现严重事件的总体报告没有意外下降。未来的研究方向包括使用来自大规模、公开的自发报告系统的数据,评估当前发现的普遍性,以及它们是否与信号检测受损相关,以及对大流行后自发报告影响是否减弱的后续分析。